Incanthera is a UK-based dermatology and oncology therapeutics company that focuses on the discovery and development of targeted medicines for cancer treatment. With a strong emphasis on innovation, we strive to address the current clinical and commercially relevant unmet needs in the field. By leveraging new technology from cutting-edge discoveries, we aim to bring these innovative solutions to the market.

Our flagship product, Sol, is a topical treatment for solar keratosis and the prevention of skin cancers. In September 2020, we announced promising results from our studies on Sol's permeation across the skin barrier and its safety profile on human skin, exceeding expectations and enhancing its commercial potential and value. To further advance Sol's technology, we have engaged in discussions with two global cosmetic companies to license the product.

These partnerships will enable us to reach a wider audience and make a significant impact in the field of dermatology and oncology therapeutics. Stay updated with our latest advancements by signing up for email alerts on our website. Join us in our mission to revolutionize cancer treatment and improve patient outcomes